FDA ApprovedFDA Approved

Semaglutide

GLP-1 Receptor Agonist | Weight Loss & Diabetes

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist FDA-approved for type 2 diabetes management (as Ozempic injectable or Rybelsus oral) and chronic weight management (as Wegovy injectable or oral). In December 2025, oral Wegovy became the first oral GLP-1 approved for weight management, offering a 25mg daily tablet option alongside the established injectable. With over 17,000 participants in clinical trials, semaglutide demonstrates significant weight loss potential (average 15-20% body weight reduction) through appetite suppression, slowed gastric emptying, and enhanced glucose control.

Daily dose

0.25-2.4mg weekly (injectable) or 3-25mg daily (oral)

Frequency

Weekly (injectable) or daily (oral)

Cycle length

Ongoing as prescribed

Storage

2-8°C (injectable) or room temp (oral)

Key benefits

FDA-approved GLP-1 agonist for type 2 diabetes and chronic weight management. Demonstrates significant weight loss (15-20% average), improved glycemic control, cardiovascular benefits, and convenient dosing options in both injectable and oral formulations. Oral Wegovy (approved Dec 2025) offers the first needle-free GLP-1 option for weight loss.

How it works

Mimics native GLP-1 hormone, binding to GLP-1 receptors throughout the body to stimulate glucose-dependent insulin release, suppress glucagon, slow gastric emptying, and reduce appetite through central nervous system pathways.

Dosage protocols

Goal

Weight Loss

Dose

2.4mg · Weekly (after titration)

Route

Subcutaneous

Goal

Diabetes - Injectable

Dose

0.5-1mg · Weekly

Route

Subcutaneous

Goal

Diabetes - Oral

Dose

7-14mg · Daily

Route

Oral (empty stomach)

Goal

Weight Loss - Oral

Dose

25mg · Daily (after titration)

Route

Oral (empty stomach)

Goal

Cardiovascular Protection

Dose

0.5-1mg · Weekly

Route

Subcutaneous

Research indications

weight Loss

FDA-Approved Weight Management — Approved as Wegovy for chronic weight management with average 15-20% body weight reduction

Sustained Appetite Control — Reduces hunger and increases satiety through central GLP-1 receptor activation

Long-Term Weight Maintenance — Clinical trials show sustained weight loss over 2+ years with continued treatment

diabetes

Comprehensive Glucose Control — FDA-approved for type 2 diabetes with HbA1c reductions of 1.5-2% and low hypoglycemia risk

Cardiovascular Benefits — Proven reduction in major cardiovascular events in high-risk diabetes patients

Flexible Treatment Options — Available as weekly injection (Ozempic), daily oral tablet for diabetes (Rybelsus), or daily oral tablet for weight management (oral Wegovy)

metabolic

Metabolic Health Improvement — Addresses multiple metabolic parameters including weight, glucose, blood pressure, and lipids

Anti-Inflammatory Effects — Reduces systemic inflammation markers beyond weight loss effects

Liver Health Benefits — Emerging evidence for improvements in non-alcoholic fatty liver disease

Administration

injectable

oral

Interactions

Monitor Combination

Insulin — May increase risk of hypoglycemia when combined with insulin; requires blood glucose monitoring and potential insulin dose adjustment

Avoid Combination

Tirzepatide — Both are incretin mimetics with overlapping mechanisms; concurrent use increases side effects without additional benefit

Synergistic

Cagrilintide — Combined as CagriSema in clinical trials - amylin analog (cagrilintide) + GLP-1 agonist (semaglutide) for enhanced weight loss

Compatible

Metformin — Commonly used together for diabetes management; complementary mechanisms with good safety profile

Compatible

Growth Hormone Peptides — No known interactions; different mechanisms of action and receptor targets

Compatible

BPC-157 — No contraindications; BPC-157 may help with GI side effects if they occur

Monitor Combination

Sulfonylureas — Increased hypoglycemia risk; may require sulfonylurea dose reduction when initiating semaglutide

Requires Timing

Oral Medications — Delayed gastric emptying may affect absorption of oral medications; consider timing adjustments

Safety notes

FDA-approved medication — use under medical supervision

Start with low dose and titrate slowly to minimize side effects

Most common side effects: nausea, diarrhea, vomiting, constipation, stomach pain, headache, fatigue, dizziness, bloating, belching, gas, heartburn, upset stomach, and hair loss

Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or MEN 2

May cause gallbladder problems including gallstones, and can increase resting heart rate

Tell all healthcare providers you take semaglutide before surgery or anesthesia due to aspiration risk

Not recommended during pregnancy (stop 2 months before planned pregnancy) or breastfeeding

Research studies

OASIS 4 Oral Semaglutide for Weight Management (2025)

307 participants | 25mg daily | 64 weeks | ~14% weight loss (~33 lb) vs 2.4% placebo

Pivotal Phase III trial supporting FDA approval of oral Wegovy. Adults with obesity or overweight (with at least one weight-related condition) lost on average ~14% of starting body weight (~33 lb from 235 lb) vs 2.4% (~6 lb) with placebo, alongside reduced-calorie diet and increased physical activity. 76% achieved ≥5% weight loss (vs 31% placebo), 60% achieved ≥10% (vs 14%), 47% achieved ≥15% (vs 6%), and 28% achieved ≥20% (vs 3%). Adults with type 2 diabetes were excluded. 18% of Wegovy pill participants discontinued vs 26% on placebo.

SELECT Cardiovascular Outcomes (2023)

17,604 participants | 2.4mg weekly | 5 years | 20% CV risk reduction

Major cardiovascular outcomes trial demonstrating 20% reduction in major adverse cardiovascular events in overweight/obese adults with established CVD.

STEP 5 Two-Year Maintenance (2022)

304 participants | 2.4mg weekly | 104 weeks | Sustained weight loss

Two-year study confirming sustained weight loss (15.2% at week 104) with continued treatment, demonstrating long-term efficacy.

STEP TEENS Adolescent Study (2022)

201 adolescents | 2.4mg weekly | 68 weeks | 16.1% BMI reduction

First trial in adolescents (12-17 years) with obesity showing significant BMI reduction and metabolic improvements.

STEP 1 Trial - Weight Management (2021)

1,961 participants | 2.4mg weekly | 68 weeks | 14.9% weight loss

Landmark phase 3 trial in adults with obesity showing 14.9% average weight loss with semaglutide 2.4mg versus 2.4% with placebo, establishing efficacy for weight management.

PIONEER Oral Semaglutide (2019)

9,543 participants | 3-14mg daily | 26-78 weeks | Oral efficacy

Series of trials establishing oral semaglutide efficacy for diabetes with HbA1c reductions comparable to injectable GLP-1 agonists.

SUSTAIN Diabetes Program (2016-2019)

Multiple trials | 0.5-1mg weekly | Various durations | HbA1c reduction

Comprehensive clinical program establishing efficacy for type 2 diabetes with average HbA1c reductions of 1.5-1.8% across trials.

Related compounds

Tirzepatide Retatrutide Orforglipron (Foundayo)Mazdutide